Related Experiment Videos
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer
1Ruttenberg Cancer Center, NYU-Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. kretzm01@doc.mssm.edu
Abstract:
Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling system that includes two types of cell surface receptors and intracellular signal transducers, the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative TGF-beta responses in tumor cells, including mutations in components of the signaling system and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory molecules. Some of these mechanisms will be discussed, with emphasis on their potential involvement in breast tumorigenesis.
Insights
Transforming growth factor-beta (TGF-beta) acts as a tumor suppressor, but its function is lost in many cancers. This loss, often seen in breast cancer, disrupts cell cycle arrest and promotes tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Transforming growth factor-beta (TGF-beta) is a critical tumor suppressor.
- Its antiproliferative effects are mediated by cell cycle arrest at the G1 phase.
- Loss of TGF-beta signaling is common in human cancers, including breast cancer.
Purpose of the Study:
- To discuss molecular mechanisms underlying the loss of antiproliferative TGF-beta responses in tumor cells.
- To emphasize the potential involvement of these mechanisms in breast tumorigenesis.
Main Methods:
- Review of molecular mechanisms affecting TGF-beta signaling.
- Analysis of mutations in TGF-beta pathway components.
- Investigation of aberrant regulatory molecules inhibiting SMAD signaling.
Main Results:
- Loss of TGF-beta tumor suppressive function is linked to compromised cell cycle arrest.
- Mutations in TGF-beta receptors or SMAD proteins can inactivate the pathway.
- Aberrant regulatory molecules can inhibit SMAD signaling, contributing to cancer progression.
Conclusions:
- Understanding the molecular basis of TGF-beta pathway inactivation is crucial for breast cancer research.
- Targeting these mechanisms may offer therapeutic strategies for breast cancer.